Annexon reported rapid, clinically meaningful improvement in strength and reduced disability within days in the first 10 U.S. and European FORWARD GBS patients treated with tanruprubart.Key Highlights:Original SEC Filing: Annexon, Inc. [ ANNX ] - 8-K - Aug. 06, 2026This is an AI-powered summary. It…
Annexon entered into a Loan and Security Agreement to access up to $200.0 million in term loans for working capital and general corporate purposes. The facility includes an initial $50.0 million funded at signing, up to $100.0 million in additional milestone-based tranches, and a further uncommitte…
Annexon, Inc. (NASDAQ:ANNX) completed enrollment of 659 patients in Phase 3 ARCHER II for vonaprument, with topline results due Q4 2026 and Phase 2 baseline traits to be presented at ASRS 2026, while the company granted inducement options to two non‑executive hires in July 2026.Previous Week Recap…
BRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. NASDAQ:ANNX, a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted induc…
BRISBANE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. NASDAQ:ANNX, a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced an oral presentation on t…
